FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309721818> ?p ?o ?g. }

• W4309721818 endingPage "1954" @default.
• W4309721818 startingPage "1954" @default.
• W4309721818 abstract "Early stereotactic body radiation therapy (SBRT) to the primary tumor combined with epidermal growth factor receptor tyrosine kinase inhibitor (EFGR-TKI) treatment may increase progression-free survival (PFS) by delaying resistance in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). In this prospective, single arm, phase II study, patients with advanced NSCLC were treated with EGFR-TKI (icotinib 125 mg tid or gefitinib 250 mg qd) for one month followed by SBRT (40–60 Gy/5–8 F/5–10 d) to the primary tumor with concurrent EGFR-TKI until disease progression. The primary endpoint was PFS and the patterns of failure. Overall survival (OS) and adverse effects (AEs) were secondary endpoints. Overall, 41 advanced NSCLC patients with EGFR mutations received treatment with 24.42 months of median follow-up time. On average, SBRT was initiated 1.49 months after EGFR-TKI administration. Tumors were found to have an average shrinkage rate of 42.50%. Median PFS was 15.23 months (95% CI 13.10–17.36), while median OS was 27.57 months (95% CI 23.05–32.09). Thirty-three patients were found to have disease progression, of which new site failure (NF) (22 patients, 66.66%) was the most common pattern, followed by original site failure (OF) (7 patients, 21.21%) and simultaneous OF/NF (ONF) (4 patients, 12.12%). There were no Aes equal to or greater than grade 3, with the most frequent AE being radiation pneumonitis. Therefore, administering therapy targeted at the primary tumor using early SBRT after EGFR-TKI initiation is a new potentially safe and effective approach to treat EGFR-mutant advanced NSCLC." @default.
• W4309721818 created "2022-11-29" @default.
• W4309721818 creator A5003336727 @default.
• W4309721818 creator A5004966636 @default.
• W4309721818 creator A5018036697 @default.
• W4309721818 creator A5021725931 @default.
• W4309721818 creator A5021936583 @default.
• W4309721818 creator A5046597133 @default.
• W4309721818 creator A5062758711 @default.
• W4309721818 creator A5070451041 @default.
• W4309721818 creator A5072148285 @default.
• W4309721818 creator A5074942308 @default.
• W4309721818 creator A5077963200 @default.
• W4309721818 creator A5084914899 @default.
• W4309721818 date "2022-11-22" @default.
• W4309721818 modified "2023-09-29" @default.
• W4309721818 title "Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study" @default.
• W4309721818 cites W1177986414 @default.
• W4309721818 cites W1594560952 @default.
• W4309721818 cites W2027242209 @default.
• W4309721818 cites W2098354451 @default.
• W4309721818 cites W2129360604 @default.
• W4309721818 cites W2462487545 @default.
• W4309721818 cites W2464433500 @default.
• W4309721818 cites W2601045707 @default.
• W4309721818 cites W2621243763 @default.
• W4309721818 cites W2749013176 @default.
• W4309721818 cites W2781648434 @default.
• W4309721818 cites W2788966918 @default.
• W4309721818 cites W2791612573 @default.
• W4309721818 cites W2806810471 @default.
• W4309721818 cites W2891445272 @default.
• W4309721818 cites W2898353758 @default.
• W4309721818 cites W2898513439 @default.
• W4309721818 cites W2909729931 @default.
• W4309721818 cites W2937223370 @default.
• W4309721818 cites W2939770857 @default.
• W4309721818 cites W2943760626 @default.
• W4309721818 cites W2951872058 @default.
• W4309721818 cites W2982013504 @default.
• W4309721818 cites W2982249748 @default.
• W4309721818 cites W2991567947 @default.
• W4309721818 cites W2995106136 @default.
• W4309721818 cites W2995626174 @default.
• W4309721818 cites W3002380503 @default.
• W4309721818 cites W3010348882 @default.
• W4309721818 cites W3032313587 @default.
• W4309721818 cites W3110810484 @default.
• W4309721818 cites W3119005666 @default.
• W4309721818 cites W3127171691 @default.
• W4309721818 cites W3128870202 @default.
• W4309721818 cites W3206836754 @default.
• W4309721818 cites W4210289312 @default.
• W4309721818 cites W4225291895 @default.
• W4309721818 cites W4280533169 @default.
• W4309721818 doi "https://doi.org/10.3390/life12121954" @default.
• W4309721818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36556319" @default.
• W4309721818 hasPublicationYear "2022" @default.
• W4309721818 type Work @default.
• W4309721818 citedByCount "1" @default.
• W4309721818 countsByYear W43097218182023 @default.
• W4309721818 crossrefType "journal-article" @default.
• W4309721818 hasAuthorship W4309721818A5003336727 @default.
• W4309721818 hasAuthorship W4309721818A5004966636 @default.
• W4309721818 hasAuthorship W4309721818A5018036697 @default.
• W4309721818 hasAuthorship W4309721818A5021725931 @default.
• W4309721818 hasAuthorship W4309721818A5021936583 @default.
• W4309721818 hasAuthorship W4309721818A5046597133 @default.
• W4309721818 hasAuthorship W4309721818A5062758711 @default.
• W4309721818 hasAuthorship W4309721818A5070451041 @default.
• W4309721818 hasAuthorship W4309721818A5072148285 @default.
• W4309721818 hasAuthorship W4309721818A5074942308 @default.
• W4309721818 hasAuthorship W4309721818A5077963200 @default.
• W4309721818 hasAuthorship W4309721818A5084914899 @default.
• W4309721818 hasBestOaLocation W43097218181 @default.
• W4309721818 hasConcept C121608353 @default.
• W4309721818 hasConcept C126322002 @default.
• W4309721818 hasConcept C143998085 @default.
• W4309721818 hasConcept C188816634 @default.
• W4309721818 hasConcept C203092338 @default.
• W4309721818 hasConcept C2776256026 @default.
• W4309721818 hasConcept C2776694085 @default.
• W4309721818 hasConcept C2777714996 @default.
• W4309721818 hasConcept C2778822529 @default.
• W4309721818 hasConcept C2779013556 @default.
• W4309721818 hasConcept C2779438470 @default.
• W4309721818 hasConcept C2779524853 @default.
• W4309721818 hasConcept C2780283643 @default.
• W4309721818 hasConcept C2780580887 @default.
• W4309721818 hasConcept C2780739268 @default.
• W4309721818 hasConcept C31760486 @default.
• W4309721818 hasConcept C535046627 @default.
• W4309721818 hasConcept C71924100 @default.
• W4309721818 hasConceptScore W4309721818C121608353 @default.
• W4309721818 hasConceptScore W4309721818C126322002 @default.
• W4309721818 hasConceptScore W4309721818C143998085 @default.
• W4309721818 hasConceptScore W4309721818C188816634 @default.
• W4309721818 hasConceptScore W4309721818C203092338 @default.

• next